Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 104
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Nutrients ; 14(19)2022 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-36235733

RESUMEN

Vitamin A (VA) deficiency is associated with increased host susceptibility to infections, but evidence on its role in the prevention and management of viral infections is still lacking. This review aimed at summarizing the effects of VA supplementation against viral infections to support clinicians in evaluating supplemental treatments. PubMed, Scopus, and Web of Science were searched. Randomized clinical trials comparing the direct effects of VA oral supplementation in any form vs. placebo or standard of care in the prevention and/or management of confirmed viral infections in people of any age were included. A narrative synthesis of the results was performed. The revised Cochrane Risk-Of-Bias tool was used to assess quality. Overall, 40 articles of heterogeneous quality were included. We found data on infections sustained by Retroviridae (n = 17), Caliciviradae (n = 2), Flaviviridae (n = 1), Papillomaviridae (n = 3), Pneumoviridae (n = 4), and Paramyxoviridae (n = 13). Studies were published between 1987 and 2017 and mostly conducted in Africa. The findings were heterogeneous across and within viral families regarding virological, immunological, and biological response, and no meaningful results were found in the prevention of viral infections. For a few diseases, VA-supplemented individuals had a better prognosis and improved outcomes, including clearance of HPV lesions or reduction in some measles-related complications. The effects of VA oral supplementation seem encouraging in relation to the management of a few viral infections. Difference in populations considered, variety in recruitment and treatment protocols might explain the heterogeneity of the results. Further investigations are needed to better identify the benefits of VA administration.


Asunto(s)
Virosis , Vitamina A , Suplementos Dietéticos , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Virosis/tratamiento farmacológico , Virosis/prevención & control , Vitamina A/uso terapéutico , Vitamina D
2.
Viruses ; 14(6)2022 06 13.
Artículo en Inglés | MEDLINE | ID: mdl-35746752

RESUMEN

Aquaculture offers a promising source of economic and healthy protein for human consumption, which can improve wellbeing. Viral diseases are the most serious type of diseases affecting aquatic animals and a major obstacle to the development of the aquaculture industry. In the background of antibiotic-free farming, the development and application of antibiotic alternatives has become one of the most important issues in aquaculture. In recent years, many medicinal plants and their active pharmaceutical ingredients have been found to be effective in the treatment and prevention of viral diseases in aquatic animals. Compared with chemical drugs and antibiotics, medicinal plants have fewer side-effects, produce little drug resistance, and exhibit low toxicity to the water environment. Most medicinal plants can effectively improve the growth performance of aquatic animals; thus, they are becoming increasingly valued and widely used in aquaculture. The present review summarizes the promising antiviral activities of medicinal plants and their active pharmaceutical ingredients against aquatic viruses. Furthermore, it also explains their possible mechanisms of action and possible implications in the prevention or treatment of viral diseases in aquaculture. This article could lay the foundation for the future development of harmless drugs for the prevention and control of viral disease outbreaks in aquaculture.


Asunto(s)
Plantas Medicinales , Virosis , Virus , Animales , Antibacterianos/uso terapéutico , Acuicultura , Preparaciones Farmacéuticas , Virosis/tratamiento farmacológico , Virosis/prevención & control , Virosis/veterinaria
3.
Nutrients ; 15(1)2022 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-36615837

RESUMEN

Vitamin D supplementation has been shown to reduce the incidence of acute respiratory infections in populations at risk. The COVID-19 pandemic has highlighted the importance of preventing viral infections in healthcare workers. The aim of this study was to assess the hypothesis that vitamin D3 supplementation at 5000 IU daily reduces influenza-like illness (ILI), including COVID-19, in healthcare workers. We conducted a prospective, controlled trial at a tertiary university hospital. A random group of healthcare workers was invited to receive 5000 IU daily vitamin D3 supplementation for nine months, while other random healthcare system workers served as controls. All healthcare workers were required to self-monitor and report to employee health for COVID-19 testing when experiencing symptoms of ILI. COVID-19 test results were retrieved. Incidence rates were compared between the vitamin D and control groups. Workers in the intervention group were included in the analysis if they completed at least 2 months of supplementation to ensure adequate vitamin D levels. The primary analysis compared the incidence rate of all ILI, while secondary analyses examined incidence rates of COVID-19 ILI and non-COVID-19 ILI. Between October 2020 and November 2021, 255 healthcare workers (age 47 ± 12 years, 199 women) completed at least two months of vitamin D3 supplementation. The control group consisted of 2827 workers. Vitamin D3 5000 IU supplementation was associated with a lower risk of ILI (incidence rate difference: -1.7 × 10-4/person-day, 95%-CI: -3.0 × 10-4 to -3.3 × 10-5/person-day, p = 0.015) and a lower incidence rate for non-COVID-19 ILI (incidence rate difference: -1.3 × 10-4/person-day, 95%-CI -2.5 × 10-4 to -7.1 × 10-6/person-day, p = 0.038). COVID-19 ILI incidence was not statistically different (incidence rate difference: -4.2 × 10-5/person-day, 95%-CI: -10.0 × 10-5 to 1.5 × 10-5/person-day, p = 0.152). Daily supplementation with 5000 IU vitamin D3 reduces influenza-like illness in healthcare workers.


Asunto(s)
COVID-19 , Gripe Humana , Virosis , Humanos , Femenino , Adulto , Persona de Mediana Edad , Colecalciferol/uso terapéutico , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Pandemias/prevención & control , Prueba de COVID-19 , Estudios Prospectivos , COVID-19/epidemiología , COVID-19/prevención & control , Vitamina D , Vitaminas/uso terapéutico , Virosis/prevención & control , Personal de Salud , Suplementos Dietéticos , Método Doble Ciego
4.
Phytother Res ; 35(11): 6148-6169, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34816512

RESUMEN

Uncontrolled inflammatory responses or cytokine storm associated with viral infections results in deleterious consequences such as vascular leakage, severe hemorrhage, shock, immune paralysis, multi-organ failure, and even death. With the emerging new viral infections and lack of effective prophylactic vaccines, evidence-based complementary strategies that limit viral infection-mediated hyperinflammatory responses could be a promising approach to limit host tissue injury. The present review emphasizes the potentials of antiinflammatory phytochemicals in limiting hyperinflammatory injury caused by viral infections. The predominant phytochemicals along with their mechanism in limiting hyperimmune and pro-inflammatory responses under viral infection have been reviewed comprehensively. How certain phytochemicals can be effective in limiting hyper-inflammatory response indirectly by favorably modulating gut microbiota and maintaining a functional intestinal barrier has also been presented. Finally, we have discussed improved systemic bioavailability of phytochemicals, efficient delivery strategies, and safety measures for effective antiinflammatory phytotherapies, in addition to emphasizing the requirement of tightly controlled clinical studies to establish the antiinflammatory efficacy of the phytochemicals. Collectively, the review provides a scooping overview on the potentials of bioactive phytochemicals to mitigate pro-inflammatory injury associated with viral infections.


Asunto(s)
Fitoquímicos , Virosis , Antiinflamatorios/farmacología , Humanos , Intestinos , Fitoquímicos/farmacología , Fitoterapia , Virosis/tratamiento farmacológico , Virosis/prevención & control
5.
Clin Nutr ESPEN ; 43: 9-15, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34024569

RESUMEN

Respiratory Viruses infections (RVI) such as rhinovirus, coronavirus, influenza virus, and adenovirus affect the respiratory and the immune systems. The role of nutrition in the respiratory and immune systems has been studied in some studies, and its importance is undeniable. In addition, one of the key findings in this disease is high inflammation that affects almost all patients. This systematic narrative review aims to answer the question, "Can an anti-inflammatory diet be effective in preventing or treating viral respiratory diseases?" A systematic review search was used for the articles extraction. All studies published in English from 1999 to 2020 investigating dietary inflammatory conditions and RVI were included. Food items with anti-inflammatory properties were selected based on the definition of the dietary inflammatory index (DII). We used Google Scholar, Pub Med, Scopus, Web of Science, Springer, Science Direct, Directory of Open Access Journals, Elsevier, Taylor and Francis, ProQuest, EBSCO, MEDLINE, and SciELO databases for extracting articles. Keywords were restricted by DII. Based on DII, food items/nutrients are involved in inflammation, some of which have anti-inflammatory and some inflammatory properties. Some foods/nutrients, in addition to their anti-inflammatory properties, have antioxidant, antiviral, and immune-enhancing properties. Considering the immune system's involvement, increased inflammation, and involvement of the pulmonary system in RVI and the remarkable role of the anti-inflammatory foods for counteracting them, it is recommended to use a predominantly anti-inflammatory diet along with prevention/control and treatment protocols. An anti-inflammatory diet (based on DII) includes turmeric, ginger, garlic, onions, saffron, dietary vitamin C, vitamin D, zinc, and omega-3 are recommended to reduce infection symptoms and duration.


Asunto(s)
Antiinflamatorios/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Micronutrientes/uso terapéutico , Extractos Vegetales/uso terapéutico , Infecciones del Sistema Respiratorio/dietoterapia , Virosis/dietoterapia , Virus , Adenoviridae , Antiinflamatorios/farmacología , Coronavirus , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/virología , Crocus , Dieta/clasificación , Ácidos Grasos Omega-3/farmacología , Humanos , Inflamación/dietoterapia , Inflamación/etiología , Micronutrientes/farmacología , Nutrientes/farmacología , Nutrientes/uso terapéutico , Estado Nutricional , Orthomyxoviridae , Extractos Vegetales/farmacología , Infecciones del Sistema Respiratorio/complicaciones , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/virología , Rhinovirus , Virosis/complicaciones , Virosis/prevención & control , Virosis/virología , Vitaminas/farmacología , Vitaminas/uso terapéutico , Zinc/farmacología , Zinc/uso terapéutico , Zingiberaceae
6.
Nutrients ; 13(4)2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33915705

RESUMEN

A diet rich in nutrients should be implemented in order to boost the immune system and prevent infections. To investigate which nutrients are commonly consumed, an anonymous survey was given to 120 individuals and their responses were collected. The respondents answered questions relating to their health status, and their consumption of nutrients and supplements that produce immunomodulating effects. The participants were also asked about any prior viral, bacterial or fungal infections experienced, and in particular, infection frequency, course, and duration. The data collected were subjected to a statistical analyses to assess the relationship between the reported frequency of infections and nutrients consumed including vitamins D3, A, C, E, selenium, zinc, iron, ß-carotene, omega-3 fatty acids as well as live active probiotic bacteria. The findings show that vitamin and mineral supplementation did not positively affect the duration, frequency, or course of infections in the surveyed sample. An exception was vitamin D3 supplementation that was correlated to sporadic incidence of viral infections. Conversely, immunity was positively affected by consumption of natural nutrients contained in whole food (vitamin C, iron, selenium, omega-3 fatty acids), evidenced by lower incidences and milder courses of infection.


Asunto(s)
Infecciones Bacterianas/prevención & control , Suplementos Dietéticos , Inmunomodulación , Micosis/prevención & control , Virosis/prevención & control , Adolescente , Adulto , Dieta , Femenino , Análisis de los Alimentos , Microbiología de Alimentos , Humanos , Masculino , Adulto Joven
7.
Expert Rev Respir Med ; 15(6): 805-821, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33858268

RESUMEN

Introduction: Viral respiratory tract infections (RTIs) have been recognized as a global public health burden. Despite current theories about their effectiveness, the true benefits of dietary supplements on the prevention and treatment of viral RTIs remain elusive, due to contradictory reports. Hence, we aimed to evaluate the effectiveness of dietary supplements on the prevention and treatment of viral RTIs.Areas covered: We systematically searched databases of PubMed, Web of Science, Scopus, and Google Scholar through 4 March 2020, to identify randomized controlled trials that evaluated the effects of consuming selected dietary supplements on the prevention or treatment of viral RTIs.Expert opinion: Thirty-nine randomized controlled trials (n = 16,797 participants) were eligible and included. Namely, vitamin D supplementation appeared to improve viral RTIs across cohorts particulate in those with vitamin D deficiency. Among the evaluated dietary supplements, specific lactobacillus strains were used most commonly with selected prebiotics that showed potentially positive effects on the prevention and treatment of viral RTIs. Further, ginseng extract supplementation may effectively prevent viral RTIs as adjuvant therapy. However, longitudinal research is required to confirm these observations and address the optimal dose, duration, and safety of dietary supplements being publicly recommended.


Asunto(s)
COVID-19/prevención & control , COVID-19/terapia , Suplementos Dietéticos , Infecciones del Sistema Respiratorio , Virosis , COVID-19/complicaciones , COVID-19/epidemiología , Suplementos Dietéticos/clasificación , Medicamentos Herbarios Chinos/uso terapéutico , Humanos , Lactobacillus/fisiología , Panax/química , Quercetina/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/terapia , SARS-CoV-2/fisiología , Virosis/epidemiología , Virosis/prevención & control , Virosis/terapia , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/dietoterapia , Deficiencia de Vitamina D/epidemiología , beta-Glucanos/uso terapéutico
8.
Int J Mol Sci ; 22(5)2021 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-33671104

RESUMEN

In recent years, there has been a growth in scientific interest in nutraceuticals, which are those nutrients in foods that have beneficial effects on health. Nutraceuticals can be extracted, used for food supplements, or added to foods. There has long been interest in the antiviral properties of nutraceuticals, which are especially topical in the context of the ongoing COVID-19 pandemic. Therefore, the purpose of this review is to evaluate the main nutraceuticals to which antiviral roles have been attributed (either by direct action on viruses or by modulating the immune system), with a focus on the pediatric population. Furthermore, the possible applications of these substances against SARS-CoV-2 will be considered.


Asunto(s)
Antivirales/uso terapéutico , COVID-19/prevención & control , Suplementos Dietéticos , Virosis/prevención & control , Niño , Humanos , Probióticos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/efectos de los fármacos
9.
Gastroenterol Hepatol ; 44(8): 587-598, 2021 Oct.
Artículo en Inglés, Español | MEDLINE | ID: mdl-33640469

RESUMEN

Patients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures.


Asunto(s)
Artritis Reumatoide/terapia , Infecciones Bacterianas/prevención & control , Terapia Biológica/efectos adversos , Inmunosupresores/efectos adversos , Enfermedades Inflamatorias del Intestino/terapia , Inhibidores de las Cinasas Janus/efectos adversos , Virosis/prevención & control , Artritis Reumatoide/inmunología , COVID-19/etiología , Hepatitis A/prevención & control , Hepatitis B/prevención & control , Herpes Zóster/prevención & control , Humanos , Enfermedades Inflamatorias del Intestino/inmunología , Gripe Humana/prevención & control , Infecciones Neumocócicas/prevención & control , Factores de Riesgo , Tuberculosis Pulmonar/prevención & control , Cobertura de Vacunación , Vacunas de Productos Inactivados/administración & dosificación
10.
Mol Biol Rep ; 48(1): 41-55, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33454908

RESUMEN

Mosquito-transmitted diseases like zika, dengue, chikungunya, and yellow fever are known to affect human health worldwide. Numerous synthetic insecticides have been used as vector control for these diseases, but there is the challenge of environmental toxicity and vector resistance. This study investigated the medicinal and insecticidal potential of Lentinus squarrosulus against Aedes aegypti. The fruiting bodies were identified morphologically as well as using internal transcribed spacer (ITS) sequences for its molecular characterization. Genomic deoxyribonucleic acid (DNA) yield was confirmed with NanoDrop Spectrophotometer ND-1000 and amplified with ITSl and ITS4 primers. The amplicons were sequenced and the National Center for Biotechnology Information (NCBI) database identified the nucleotides. Its ethanol extract was subjected to phytochemical screening and gas chromatography mass spectrometry (GC-MS) analysis and tested against the pupa and fourth instar larva of Aedes aegypti with percentage mortality monitored. The Macrofungus was identified morphologically and confirmed with molecular characterization as Lentinus squarrosulus (LS). The gene sequence was deposited in GenBank (Accession number MK629662.1). GC-MS analysis showed that its ethanol extract has 25 bioactive compounds with 9,12-Octadecadienoic acid, ethyl ester having the highest percentage of 43.32% as well as methyl-2-oxo-1-pyrrolidine acetate and 17-octadecynoic acid having the lowest percentage (0.09%). The macrofungus contained varied concentrations of phytochemicals including phenols (159 mg/g GAE), tannins (1.6 mg/g TAE), and flavonoids (31.4 mg/g QE). The ethanol extract had significant potent effects on Aedes aegypti larva and pupa which could be due to the occurrence and abundance of 9,12-octadecadienoic acid in LS. The LC50 of the extract for larvicidal and pupicidal activities were 2.95 mg/mL and 3.55 mg/mL, respectively, while its LC90 were 6.31 mg/mL and 5.75 mg/mL respectively. Lentinus squarrosulus had insecticidal effects against the Aedes aegypti larva and pupa and possessed great potential as a source of alternative medicine and eco-friendly insecticides.


Asunto(s)
Aedes/efectos de los fármacos , Lentinula/química , Extractos Vegetales/farmacología , Virosis/prevención & control , Aedes/patogenicidad , Animales , Etanol/química , Cromatografía de Gases y Espectrometría de Masas , Humanos , Insecticidas/química , Insecticidas/farmacología , Larva/efectos de los fármacos , Larva/patogenicidad , Mosquitos Vectores/efectos de los fármacos , Mosquitos Vectores/patogenicidad , Fitoquímicos/química , Fitoquímicos/farmacología , Extractos Vegetales/química , Hojas de la Planta/química , Virosis/epidemiología
11.
Nutrients ; 12(10)2020 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-33081138

RESUMEN

Viral respiratory tract infection (RTI) is the most frequent cause of infectious illnesses including the common cold. Pharmacological solutions for treating or preventing viral RTIs are so far limited and thus several self-care products are available in the market. Some dietary supplements such as probiotics have been shown to modulate immune system function and their role in reducing the risk and the course of RTIs has been investigated extensively within the past decade. However, the mechanism of action and the efficacy of probiotics against viral RTIs remains unclear. We searched PubMed, Google Scholar, and Web of Knowledge for pre-clinical and clinical studies investigating the effect of probiotics on respiratory virus infections, immune response, and the course of upper and lower respiratory tract illness. The literature summarized in this narrative review points out that specific probiotic strains seem effective in pre-clinical models, through stimulating the immune system and inhibiting viral replication. Clinical studies indicate variable efficacy on upper respiratory illnesses and lack proof of diagnosed viral infections. However, meta-analyses of clinical studies indicate that probiotics could be beneficial in upper respiratory illnesses without specific etiology. Further studies aiming at discovering the mechanisms of action of probiotics and clinical efficacy are warranted.


Asunto(s)
Suplementos Dietéticos , Sistema Inmunológico/efectos de los fármacos , Probióticos/administración & dosificación , Probióticos/farmacología , Infecciones del Sistema Respiratorio/inmunología , Infecciones del Sistema Respiratorio/prevención & control , Virosis/inmunología , Virosis/prevención & control , Bifidobacterium , Humanos , Inmunomodulación/efectos de los fármacos , Lactobacillus , Infecciones del Sistema Respiratorio/virología , Estimulación Química , Virosis/virología , Replicación Viral/efectos de los fármacos
12.
Nutrients ; 12(9)2020 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-32825564

RESUMEN

This review summarizes the latest advancements in phytochemicals as functional antiviral agents. We focused on flavonoids, like apigenin, vitexin, quercetin, rutin and naringenin, which have shown a wide range of biological effects including antiviral activities. The molecular mechanisms of their antiviral effects mainly consist in the inhibition of viral neuraminidase, proteases and DNA/RNA polymerases, as well as in the modification of various viral proteins. Mixtures of different flavonoids or combination of flavonoids with antiviral synthetic drugs provide an enhancement of their antiviral effects. Recent strategies in drug delivery significantly contribute to overcoming the low bioavailability of flavonoids. Frequent viral infections worldwide have led to the need for new effective antiviral agents, which can be identified among the various phytochemicals. In this light, screening the antiviral activities of a cocktail of flavonoids would be advantageous in order to prevent viral infections and improve current antiviral therapies.


Asunto(s)
Antivirales , Sistemas de Liberación de Medicamentos , Flavonoides/administración & dosificación , Flavonoides/farmacología , Apigenina/química , Apigenina/farmacología , Disponibilidad Biológica , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Flavanonas/química , Flavanonas/farmacología , Flavonoides/química , Flavonoides/farmacocinética , Humanos , Neuraminidasa/antagonistas & inhibidores , Quercetina/química , Quercetina/farmacología , Rutina/química , Rutina/farmacología , Inhibidores de Proteasa Viral , Proteínas Virales/metabolismo , Virosis/tratamiento farmacológico , Virosis/prevención & control , Virosis/virología , Virus/enzimología , Virus/metabolismo
13.
Front Immunol ; 11: 1221, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32574271

RESUMEN

Lactoferrin is a nutrient classically found in mammalian milk. It binds iron and is transferred via a variety of receptors into and between cells, serum, bile, and cerebrospinal fluid. It has important immunological properties, and is both antibacterial and antiviral. In particular, there is evidence that it can bind to at least some of the receptors used by coronaviruses and thereby block their entry. Of importance are Heparan Sulfate Proteoglycans (HSPGs) and the host receptor angiotensin-converting enzyme 2 (ACE2), as based on other activities lactoferrin might prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from attaching to the host cells. Lactoferrin (and more specifically enteric-coated LF because of increased bioavailability) may consequently be of preventive and therapeutic value during the present COVID-19 pandemic.


Asunto(s)
Proteoglicanos de Heparán Sulfato/metabolismo , Lactoferrina/fisiología , Lactoferrina/uso terapéutico , Peptidil-Dipeptidasa A/metabolismo , Receptores Virales/metabolismo , Enzima Convertidora de Angiotensina 2 , Animales , Antibacterianos/uso terapéutico , Infecciones Bacterianas/prevención & control , Suplementos Dietéticos , Humanos , Lactoferrina/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Coronavirus , Virosis/prevención & control
14.
Nutrients ; 12(4)2020 Apr 23.
Artículo en Inglés | MEDLINE | ID: mdl-32340216

RESUMEN

Public health practices including handwashing and vaccinations help reduce the spread and impact of infections. Nevertheless, the global burden of infection is high, and additional measures are necessary. Acute respiratory tract infections, for example, were responsible for approximately 2.38 million deaths worldwide in 2016. The role nutrition plays in supporting the immune system is well-established. A wealth of mechanistic and clinical data show that vitamins, including vitamins A, B6, B12, C, D, E, and folate; trace elements, including zinc, iron, selenium, magnesium, and copper; and the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid play important and complementary roles in supporting the immune system. Inadequate intake and status of these nutrients are widespread, leading to a decrease in resistance to infections and as a consequence an increase in disease burden. Against this background the following conclusions are made: (1) supplementation with the above micronutrients and omega-3 fatty acids is a safe, effective, and low-cost strategy to help support optimal immune function; (2) supplementation above the Recommended Dietary Allowance (RDA), but within recommended upper safety limits, for specific nutrients such as vitamins C and D is warranted; and (3) public health officials are encouraged to include nutritional strategies in their recommendations to improve public health.


Asunto(s)
Infecciones por Coronavirus/inmunología , Sistema Inmunológico/fisiología , Estado Nutricional , Neumonía Viral/inmunología , COVID-19 , Infecciones por Coronavirus/prevención & control , Ácidos Grasos Omega-3/administración & dosificación , Humanos , Micronutrientes/administración & dosificación , Fenómenos Fisiológicos de la Nutrición , Pandemias/prevención & control , Neumonía Viral/prevención & control , Oligoelementos/administración & dosificación , Virosis/inmunología , Virosis/prevención & control , Vitaminas/administración & dosificación
15.
Rev. bras. med. trab ; 18(1): 109-112, jan-mar.2020.
Artículo en Portugués | LILACS | ID: biblio-1116156

RESUMEN

Introdução: A acupuntura integra o escopo das práticas integrativas e complementares em saúde, sendo de extrema importância o uso das normas de biossegurança durante essa técnica. Objetivo: Refletir sobre biossegurança em acupuntura visando diminuir riscos ocupacionais relacionados ao evento adverso de infecção, tanto para o profissional quanto para o paciente. Método: Para a elaboração desta reflexão teórica, utilizaram-se estudos da literatura selecionados de forma intencional. As reflexões sobre biossegurança em acupuntura ocorreram no período de junho a outubro de 2019. Resultados: As infecções constituem os efeitos adversos associados à acupuntura mais relatados na literatura. Nessa prática, verifica-se elevado potencial de inoculação de microrganismos. Assim, devem-se seguir os princípios de promoção em biossegurança conscientizando os profissionais sobre a importância de tais cuidados para a própria segurança e a do paciente, sem minimizar a eficácia do tratamento. Conclusões: Recomenda-se adoção das práticas universais de biossegurança durante a realização de procedimentos de acupuntura.


Background: Acupuncture is an integrative and complementary practice for which biosafety standards are essential. Objective: To elicit a reflection on biosafety in acupuncture to reduce occupational hazards associated with infection as adverse effect for both provider and patient. Methods: The present theoretical essay is grounded on references intentionally selected from June through October 2019. Results: Infection is the adverse effect most frequently reported for acupuncture practice, which involves considerable risk of microorganism inoculation. Provider awareness should be raised to comply with biosafety principles and thus ensure their and patient safety without any negative implications for the effectiveness of treatment. Conclusion: We recommended providers to adopt universal biosafety practices during acupuncture procedures.


Asunto(s)
Humanos , Infecciones Bacterianas/prevención & control , Virosis/prevención & control , Terapia por Acupuntura , Seguridad del Paciente , Terapia por Acupuntura/efectos adversos
16.
Vaccine ; 37(43): 6248-6254, 2019 10 08.
Artículo en Inglés | MEDLINE | ID: mdl-31500964

RESUMEN

Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current "gaps," and prospect what could be done to improve our position. Herein we describe the summit proceedings, "Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases," held October 2-3, 2018, at the Trudeau Institute in Saranac Lake, NY.


Asunto(s)
Enfermedades Transmisibles Emergentes , Vectores de Enfermedades , Vacunas Virales/farmacología , Virosis/prevención & control , Animales , Ensayos Clínicos como Asunto , Enfermedades Transmisibles Emergentes/prevención & control , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Gripe Humana/etiología , Gripe Humana/prevención & control , Embarazo , Complicaciones Infecciosas del Embarazo/etiología , Investigación Biomédica Traslacional , Vacunas Virales/uso terapéutico , Infección por el Virus Zika/etiología , Infección por el Virus Zika/prevención & control
17.
J Pediatr ; 209: 220-225, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30885645

RESUMEN

OBJECTIVES: To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. STUDY DESIGN: We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED). RESULTS: In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P = .29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P = .57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P < .001). Time to subsequent transfusion and red cell utilization were similar in every group (P > .05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. CONCLUSIONS: Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.


Asunto(s)
Transfusión de Plaquetas/efectos adversos , Reacción a la Transfusión/epidemiología , Adolescente , Infecciones Bacterianas/prevención & control , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Control de Infecciones , Transfusión de Plaquetas/estadística & datos numéricos , Utilización de Procedimientos y Técnicas/estadística & datos numéricos , Virosis/prevención & control
18.
Expert Rev Anti Infect Ther ; 16(10): 781-791, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30198355

RESUMEN

INTRODUCTION: The development of biologic therapies for treating patients with rheumatic, hematologic, or oncological diseases has increased in the last few years, spreading their use in clinical practice. Areas covered: Clinical experience has evidenced substantial risks for some viral infections and/or reactivations such as viral hepatitis, herpetic infections, and other viruses, as a consequence of specific immune pathway blockages. Biological therapies produce a variable risk of reactivation of viral infections, which is particularly uncertain in the case of the most recently introduced agents. Here we make an extensive review of the viral infections associated with the use of biological drugs and provide a series of recommendations for its prevention and management. Expert commentary: To prevent these infections/reactivations, the practitioner must be aware of the infection-risk profile, performing accurate screening during and after the use of any biologic agent. In some instances, expert recommendations are made for some therapies, while in other scenarios recommendations have not yet been defined making experimental and clinical research an essential approach to elucidate multiple issues yet not resolved in this field.


Asunto(s)
Productos Biológicos/administración & dosificación , Terapia Biológica/efectos adversos , Virosis/epidemiología , Productos Biológicos/efectos adversos , Terapia Biológica/métodos , Humanos , Tamizaje Masivo/métodos , Activación Viral , Virosis/etiología , Virosis/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA